Alexander Knaupp
Overview
Explore the profile of Alexander Knaupp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duivelshof B, Bouvarel T, Pirner S, Larraillet V, Knaupp A, Koll H, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38068945
Charge heterogeneity among therapeutic monoclonal antibodies (mAbs) is considered an important critical quality attribute and requires careful characterization to ensure safe and efficacious drug products. The charge heterogeneity among mAbs...
2.
Lippold S, Mistry K, Lenka S, Whang K, Liu P, Pitschi S, et al.
Front Immunol
. 2023 Oct;
14:1260446.
PMID: 37790943
Human Fc gamma receptor IIa (FcγRIIa) or CD32a has two major allotypes with a single amino acid difference at position 131 (histidine or arginine). Differences in FcγRIIa allotypes are known...
3.
Marshall M, Knaupp A, Spick C, Koese I, Maier M, Cragg M, et al.
J Immunol
. 2023 Apr;
210(11):1837-1848.
PMID: 37093649
The classical complement system represents a central effector mechanism of Abs initiated by the binding of C1q to target bound IgG. Human C1q contains six heterotrimeric globular head groups that...
4.
Lippold S, Hook M, Spick C, Knaupp A, Whang K, Ruperti F, et al.
Anal Chem
. 2023 Jan;
95(4):2260-2268.
PMID: 36638115
T-cell engaging bispecific antibodies (TCBs) targeting CD3 and tumor-specific antigens are very promising therapeutic modalities. Since CD3 binding is crucial for the potency of TCBs, understanding the functional impact of...
5.
Gstottner C, Knaupp A, Vidarsson G, Reusch D, Schlothauer T, Wuhrer M, et al.
Front Immunol
. 2022 Sep;
13:980291.
PMID: 36159782
The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood. Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering...
6.
Bouvarel T, Duivelshof B, Camperi J, Schlothauer T, Knaupp A, Stella C, et al.
J Chromatogr A
. 2022 Sep;
1682:463518.
PMID: 36155073
Affinity liquid chromatography using FcRn and FcγRIIIa columns can provide important information on the drug effector functions and the unique PK/PD properties of therapeutic mAbs. In this study, we propose...
7.
Gstottner C, Hook M, Christopeit T, Knaupp A, Schlothauer T, Reusch D, et al.
Anal Chem
. 2021 Nov;
93(45):15133-15141.
PMID: 34739220
Monoclonal antibody (mAb) pharmaceuticals consist of a plethora of different proteoforms with different functional characteristics, including pharmacokinetics and pharmacodynamics, requiring their individual assessment. Current binding techniques do not distinguish between...
8.
Lippold S, Knaupp A, de Ru A, Tjokrodirijo R, Van Veelen P, van Puijenbroek E, et al.
MAbs
. 2021 Oct;
13(1):1982847.
PMID: 34674601
The crystallizable fragment (Fc) of immunoglobulin G (IgG) activates key immunological responses by interacting with Fc gamma receptors (FcɣR). FcɣRIIIb contributes to neutrophil activation and is involved in antibody-dependent cellular...
9.
Kraft T, Richter W, Emrich T, Knaupp A, Schuster M, Wolfert A, et al.
MAbs
. 2019 Nov;
12(1):1683432.
PMID: 31769731
The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several...
10.
Edelmann M, Kettenberger H, Knaupp A, Schlothauer T, Otteneder M
J Labelled Comp Radiopharm
. 2019 Aug;
62(11):751-757.
PMID: 31369163
The number of therapeutic antibodies in research and development as well as their complexity increases from year to year. Novel therapeutic protein formats, such as Fc-fusions, bispecific, or multivalent antibodies,...